(Total Views: 494)
Posted On: 05/08/2023 6:06:56 PM
Post# of 154862
Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology...Published May 8th, 2023
2.1.19 CCR5..."Recently it was observed that blocking CCR5 results in Anticare activity.;
Such a PHENOMENON was show-cased by the emergence of a humanized Monoclonal Antibody Leronlimab (Pro140) an CCR5 Antagonist.
It was observed from the preclincal trial that the binding of Leronlimab to human CCR5 leads to a Blockage of the CCR5 mediating signalling pathway, thereby PreventingTNBC cell Invasion " [70-71] ....mentions Drs. Pestell and Chris Recknor.
2.1.19 CCR5..."Recently it was observed that blocking CCR5 results in Anticare activity.;
Such a PHENOMENON was show-cased by the emergence of a humanized Monoclonal Antibody Leronlimab (Pro140) an CCR5 Antagonist.
It was observed from the preclincal trial that the binding of Leronlimab to human CCR5 leads to a Blockage of the CCR5 mediating signalling pathway, thereby PreventingTNBC cell Invasion " [70-71] ....mentions Drs. Pestell and Chris Recknor.
(4)
(0)
